Healthcare and life sciences
Pharmaceuticals
Developing and manufacturing medicines.
Nobody searches for a pharmaceutical company. They ask whether a substitute works, which Indian plant holds EU GMP, how a biosimilar differs from a generic, how long a painkiller is safe. Four different buyers, one pattern: the molecule question is settled by an engine, and the maker is chosen inside that answer or not at all. Indian manufacturers publish almost nothing at that layer, which is the opening.
Where the answer is being lost
The molecule is explained by everyone except the people who make it.
Pharma sells through gatekeepers. A sourcing head at a formulator asks "Which Indian API manufacturers have EU GMP certification" and gets a directory row. A hospital procurement head asks how a biosimilar differs from a generic and gets the originator's own education material. A pharmacist's customer asks whether the substitute is as good and gets a news explainer. None of these people are browsing your website. They are being handed a shortlist by a model, assembled from whatever is legible, and every enquiry that never arrives was a qualification cycle, a formulary slot or a substitution that went to a maker who published.
How we win this
The programme for pharmaceuticals
Answer at the molecule
Nobody types a company name into an engine before they need one. They ask about bioequivalence, about EU GMP, about how long a tablet is safe. So the work starts with what your regulatory, quality and medical affairs teams already write for filings and internal training, and turns it into pages an engine can quote and attribute. answer-pages and blogs carry most of it.
Make the record machine-readable
A pharma company is a list of facts: sites, inspection outcomes, certificates and their expiry, molecules, approval pathways, the people who signed the content. Most of that sits in a PDF or an image of a table. schema turns it into structured data a model can resolve without guessing, and puts a named, qualified reviewer on every regulated page.
The limits are the content
Two rules do the work, and they are not the same rule. Prescription products may not be advertised to the public, so the generics, API and biosimilar material is written for prescribers, procurement and regulatory readers. Separately, the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954 makes it a criminal offence to advertise treatment to the public for a scheduled list of conditions, and it binds whoever publishes the copy, your marketing team and the agency writing it alike. We scope consumer-facing work against that schedule and against the approved label before it is drafted, which is why the pages carry the ceiling dose, the contraindication and the point at which someone should stop and ask a pharmacist. Those are the lines a model reaches for.
Content ends at the longlist
Be clear about where this stops. An API contract is signed after an audit, a formulary place after a committee vote, a distribution deal after a commercial negotiation. None of that is decided by a page. What a page decides is whether you are in the set being considered at all, and whether the buyer arrives having already read your regulatory record.
The mix that carries it
Content
Answer and comparison pages
Cost, process, eligibility and comparison pages built for direct extraction, not for a reader who scrolls.
Content
GEO blogs and authority content
The definitive written answer to the questions your buyers put to an engine, structured so it can be lifted and attributed.
Foundation
Entity and schema engineering
Structured data and entity definition so engines know exactly what you are, where you operate, and what you are credible in.
Authority
Digital public outreach
Earned mentions, trade coverage and third-party citations — the corroboration a model checks before it names you.
Content
Video and YouTube
Video run as a primary AI source, for the dense, entity-rich transcripts models read and quote.
Authority
Directories and profile consistency
Every listing, registry and profile saying the same thing, so the entity resolves to one business instead of three.
Distribution
Visual proof for categories bought on look, place and trust before anything is read.
The constraint we work inside
This page carries two regimes, not one. Prescription products, your generics, APIs and biosimilars, cannot be advertised to the public, so that material is built for prescribers, hospital and distributor procurement, and regulatory readers. Over-the-counter products can be promoted to consumers, and are, every day. What governs them is content: no claim beyond the approved label, and nothing that advertises treatment to the public for a condition scheduled under the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954. Breaching that Act is a criminal offence and it binds the publisher as well as the manufacturer, which means us. So we check the schedule and the label before we draft, not after legal sees it. That is not a restriction on tone. It is the reason the pages are worth citing.
Specialisations
4 total
The pitch is different for each one, because the buyer, the trigger and the rules on what may be published are different for each one. Open the one that is yours.
A patient hands over a prescription, the pharmacist offers a substitute, and the doubt that decides the sale is settled on a phone before the packet leaves the counter.
The question deciding this today
“Are generic medicines as effective as branded ones in India”
- Who they sell to
- Patients and pharmacies buying off patent equivalents
- Who signs
- The pharmacy, distributor, or the patient
- What starts it
- Prescription, cost pressure, patent expiry, tender award, substitution
- Cost of staying invisible
- Paying brand prices for identical molecules
The question a pharmacist gets asked twice a day, "Are generic medicines as effective as branded ones in India", is currently answered by a news explainer, a government FAQ and a health portal. No manufacturer is named. Nothing about bioequivalence testing, plant approvals or batch release appears at all. Meanwhile your real buyer, a distributor's category head or a chain pharmacy's purchase team, is checking makers the same way, and finds a product list and a contact form.
What we would run
- 01GEO blogs and authority content
A set of plain explainers under your quality head's name: what bioequivalence testing actually measures, how a batch is released, what a WHO-GMP or USFDA site approval covers, why excipients differ and dosage does not.
The substitution doubt is answered at the counter and on a phone. A model reaching for an explanation of bioequivalence will take a named manufacturer's over an unsigned portal's.
- 02Answer and comparison pages
Molecule-level pages rather than brand pages: which of your products are equivalents of which reference drugs, the strengths and forms you make, the sites they come from, and the approvals each site holds.
Distributors and chain buyers arrive with a molecule and a volume in mind. This is the page that lets an engine answer them with your name attached to it.
- 03Entity and schema engineering
Your organisation, plants, approvals and therapeutic categories defined as entities, each site tied to its inspection status and each product tied to its molecule, strength and form.
A manufacturer is a set of facts a model can either resolve or skip. Structured, your plant list survives being compressed into a two-line answer.
- 04Digital public outreach
Placed commentary and trade coverage on capacity, filings and quality record in pharma trade press, plus consistent references from the industry bodies and export councils you already belong to.
Procurement and distribution buyers verify a maker through third-party sources. Those same sources are what an engine treats as corroboration when it decides whom to name.
- 05AI Presence tracking
Tracking which makers get named on substitution, quality and equivalence questions across the main engines, by molecule and by market, with the wording of each answer kept over time.
This is the only reliable way to see whether a distributor's research now includes you, because none of that reading ever reaches your own site as a visit.
What we would not recommend
- Reviews and testimonials. Rating a medicine means rating its effect, and that is a therapeutic claim nobody may make outside the approved label.
- Quora. These are prescription products, which may not be advertised to the public, and an individualised reply to a patient's medication question also starts a pharmacovigilance obligation your team has to record and report.
- Instagram. Prescription products cannot be promoted to the public, and the category head at a distributor makes no rate contract decision from a feed.
What a lead looks like
A purchase manager at a pharmacy chain rings during the rate contract round. She has your molecule list open and already knows which site each strength is released from, so the call starts at what approvals that site holds, how quickly batches release, and whether supply survives the length of the contract. Behind her, a distributor's category desk has been reading the same pages for a month.
What we measure
- Named in substitution and equivalence answers
- Plant approvals machine-readable per product
- Enquiries from distributors and chain buyers
- No promotional claim in published copy
- Rival makers named alongside you, molecule by molecule
What changes
A sourcing head who has read your EU GMP and DMF status pages writes asking about audit history and lead times for a named molecule. A hospital procurement head raises your biosimilar before the formulary meeting, not after it. A chain pharmacy buyer knows your plant approvals before the distributor calls. Fewer enquiries than a consumer brand gets, arriving later in the cycle and further qualified, from people who came with the molecule already decided.
Start here
See who gets named in pharmaceuticals today
We put your buyers' real questions to the live models and come back with the businesses they name, the sources behind those answers, and the gap between that list and yours.